Three vs 6 Cycles of Adjuvant Chemotherapy for Retinoblastoma
Mené en Chine sur 187 patients atteints d'un rétinoblastome à haut risque de récidive (durée médiane de suivi : 79 mois), cet essai randomisé évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de 3 ou 6 cycles d'une chimiothérapie adjuvante de type CEV (carboplatine, étoposide et vincristine) après une énucléation
In this issue of JAMA, Ye and colleagues1 report the results of their dual-institution randomized clinical trial of 3 cycles vs 6 cycles of standard-dose carboplatin etoposide vincristine (CEV) as adjuvant chemotherapy for pT3a (massive choroidal infiltration), pT3b (retrolaminar optic nerve invasion), and pT3c (scleral invasion) in patients with group D and E retinoblastoma undergoing upfront enucleation. Of 187 patients who underwent randomization, there were 179 included in the modified intention-to-treat analysis (4 guardians withdrew consent, and 4 patients were found not to have pT3a-c pathology on subsequent review). Substantial strengths of this trial included a median follow-up of 6.5 years, and no study participants were lost to follow-up. (...)
JAMA Ophthalmology , commentaire en libre accès, 2023